Findings from a landmark clinical trial in pediatric Crohn's disease show a clear benefit of adding methotrexate to treatment with the tumor necrosis factor inhibitor (TNFi) adalimumab (Humira), but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results